Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom

Journal of Clinical Microbiology

Volumn 51, Issue 3, 2013, Pages 967-972

  Borman, Andrew M ^a   Szekely, Adrien ^a   Linton, Chistopher J ^a   Palmer, Michael D ^a   Brown, Phillipa ^a   Johnson, Elizabeth M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMPHOTERICIN B; CLOTRIMAZOLE; ECONAZOLE; INTERNAL TRANSCRIBED SPACER 2; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA AFRICANA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CHLAMYDOSPORE; CLINICAL FEATURE; CULTURE MEDIUM; FUNGAL VIRULENCE; FUNGUS GROWTH; FUNGUS ISOLATION; GALLERIA MELLONELLA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SPECIES DIFFERENTIATION; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; DNA, FUNGAL; DNA, INTERGENIC; FEMALE; GENITALIA, FEMALE; GREAT BRITAIN; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84874092703     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02816-12     Document Type: Article

References (46)

1. Marr KA. 2004. Invasive Candida infections: the changing epidemiology. Oncology 18(14 Suppl 13):9-14.
2. Nucci M, Marr KA. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521-526.
3. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ. 1999. International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participaant Group (Europe). Diagn. Microbiol. Infect. Dis. 35:19-25.
4. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 31:327-332.
5. Ruhnke M. 2006. Epidemiology of Candida albicans infections and role of non-Candida albicans yeasts. Curr. Drug Targets 7:495-504.
6. Snydman DR. 2003. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 123:500S-503S.
7. Wingard JR. 1994. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. 19(Suppl 1):49-53.
8. Wright WL, Wenzel RP. 1997. Nosocomial Candida. Epidemiology, transmission and prevention. Infect. Dis. Clin. North Am. 11:411-425.
9. Moran GP, Coleman DC, Sullivan DJ. 2011. Comparative genomics and evolution of pathogenicity in human pathogenic fungi. Eukaryot. Cell 10:34-42.
10. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. 1995. Candida dubliniensis sp. nov.: phenotypic and molecular character- ization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 141:1507-1521.
11. Khan Z, Ahmad S, Joseph L, Chandy R. 2012. Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen. PLoS One 7:e32952. doi:10.1371/journal.pone.0032952.
12. Sullivan DJ, Coleman DC. 1997. Candida dubliniensis: an emerging opportunistic pathogen. Curr. Top. Med. Mycol. 8:15-25.
13. Sullivan DJ, Moran GP, Coleman DC. 2005. Candida dubliniensis: ten years on. FEMS Microbiol. Lett. 253:9-17.
14. Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, Coleman DC. 2004. Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res. 4:369-376.
15. Moran GP, Coleman DC, Sullivan DJ. 2012. Candida albicans versus Candida dubliniensis: why is C. albicans more pathogenic? Int. J. Microbiol. 2012:205291. doi:10.1155/2012/205921.
16. Romeo O, de Leo F, Criseo G. 2011. Adherence ability of Candida africana: a comparative study with Candida albicans and Candida dubliniensis. Mycoses 54:e57-e61.
17. Forche A, Schonian G, Graser Y, Vilgalys R, Mitchell TG. 1999. Genetic structure of typical and atypical populations of Candida albicans from Africa. Fungal Genet. Biol. 28:107-125.
18. Tietz HJ, Kussner A, Thanos M, De Andrade MP, Presber W, Schonian G. 1995. Phenotypic and genotypic characterization of unusual vaginal isolates of Candida albicans from Africa. J. Clin. Microbiol. 33:2462-2465.
19. Alonso-Vargas R, Elorduy L, Eraso E, Cano FJ, Guarro J, Ponton J, Quindos G. 2008. Isolation of Candida africana, probable atypical strains of Candida albicans, from a patient with vaginitis. Med. Mycol. 46:167-170.
20. Jacobsen MD, Boekhout T, Odds FC. 2008. Multilocus sequence typing confirms synonymy but highlights differences between Candida albicans and Candida stellatoidea. FEMS Yeast Res. 8:764-770.
21. Romeo O, Criseo G. 2009. Morphological, biochemical and molecular characterization of the first Italian Candida africana isolate. Mycoses 52: 454-457.
22. Romeo O, Criseo G. 2011. Candida africana and its closest relatives. Mycoses 54:475-486.
23. Tietz HJ, Hopp M, Schmalreck A, Sterry W, Czaika V. 2001. Candida africana sp. nov., a new human pathogen or a variant of Candida albicans? Mycoses 44:437-445.
24. Romeo O, Criseo G. 2008. First molecular method for discriminating between Candida africana, Candida albicans and Candida dubliniensis by using hwp1 gene. Diagn. Microbiol. Infect. Dis. 62:230-233.
25. Romeo O, Criseo G. 2009. Molecular epidemiology of Candida albicans and its closely related yeasts Candida dubliniensis and Candida africana. J. Clin. Microbiol. 47:212-214.
26. Campbell CK, Davey KG, Holmes AD, Szekely A, Warnock DW. 1999. Comparison of the API Candida system with the AUXACOLOR2 system for identification of common yeast pathogens. J. Clin. Microbiol. 37:821-823.
27. Borman AM, Linton CJ, Oliver D, Palmer MD, Szekely A, Johnson EM. 2010. Rapid molecular identification of pathogenic yeasts by pyrosequencing analysis of 35 nucleotides of internal transcribed spacer 2. J. Clin. Microbiol. 48:3648-3653.
28. Borman AM, Linton CJ, Oliver D, Palmer MD, Szekely A, Odds FC, Johnson EM. 2009. Pyrosequencing analysis of 20 nucleotides of internal transcribed spacer 2 discriminates Candida parapsilosis, Candida metapsilosis, and Candida orthopsilosis. J. Clin. Microbiol. 47:2307-2310.
29. Borman AM, Petch R, Linton CJ, Palmer MD, Bridge PD, Johnson EM. 2008. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J. Clin. Microbiol. 46:933-938.
30. Borman AM, Campbell CK, Linton CJ, Johnson EM. 2006. Polycytella hominis is a mutated form of Scedosporium apiospermum. Med. Mycol. 44:33-39.
31. Linton CJ, Borman AM, Cheung G, Holmes AD, Szekely A, Palmer MD, Bridge PD, Campbell CK, Johnson EM. 2007. Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom Mycology Reference Laboratory. J. Clin. Microbiol. 45:1152-1158.
32. Borman AM, Fraser M, Linton CJ, Palmer MD, Johnson EM. 2010. An improved method for the preparation of total genomicDNAfrom isolates of yeast and mould using Whatman FTA filter papers. Mycopathologia 169:445-449.
33. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution susceptibility testing of yeasts: approved standard, 3rd ed. Document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
34. Cotter G, Doyle S, Kavanagh K. 2000. Development of an insect model for the in vivo pathogenicity testing of yeasts. FEMS Immunol. Med. Microbiol. 27:163-169.
35. Fallon J, Kelly J, Kavanagh K. 2012. Galleria mellonella as a model for fungal pathogenicity testing. Methods Mol. Biol. 845:469-485.
36. Fuchs BB, Eby J, Nobile CJ, El Khoury JB, Mitchell AP, Mylonakis E. 2010. Role of filamentation in Galleria mellonella killing by Candida albicans. Microbes Infect. 12:488-496.
37. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. 2010. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 1:475-482.
38. Odds FC, Bougnoux ME, Shaw DJ, Bain JM, Davidson AD, Diogo D, Jacobsen MD, Lecomte M, Li SY, Tavanti A, Maiden MC, Gow NA, d'Enfert C. 2007. Molecular phylogenetics of Candida albicans. Eukaryot. Cell. 6:1041-1052.
39. Tintelnot K, Haase G, Siebold M, Bergmann F, Staemmler M, Franz T, Naumann D. 2000. Evaluation of phenotypic markers for selection and identification of Candida dubliniensis. J. Clin. Microbiol. 38:1599-1608.
40. Junqueira JC, Fuchs BB, Muhammed M, Coleman JJ, Suleiman JMAH, Vilela SFG, Costa ACBP, Rasteiro VMC, Jorge AOC, Mylonakis E. 2011. Oral Candida albicans isolates from HIV-positive individuals have similar in vitro biofilm-forming ability and pathogenicity as invasive Candida isolates. BMC Microbiol. 11:247-256.
41. Nnadi NE, Ayanbimpe GM, Scordina F, Okolo MO, Enweani IB, Criseo G, Romeo O. 2012. Isolation and molecular characterisation of Candida africana from Jos, Nigeria. Med. Mycol. 50:765-767.
42. Sudbery P, Gow N, Berman J. 2004. The distinct morphogenic states of Candida albicans. Trends Microbiol. 12:317-324.
43. Sullivan DJ, Moran GP. 2011. Differential virulence of Candida albicans and C. dubliniensis: a role for Tor1 kinase? Virulence 2:77-81.
44. Finkel JS, Mitchell AP. 2010. Genetic control of Candida albicans biofilm development. Nat. Rev. Microbiol. 9:109-118.
45. Stokes C, Moran GP, Spiering MJ, Cole GT, Coleman DC, Sullivan DJ. 2007. Lower filamentation rates of Candida dubliniensis contribute to its lower virulence in comparison with Candida albicans. Fungal Genet. Biol. 44:920-931.
46. Vilela MMS, Kamei K, Sano A, Tanaka R, Uno J, Takahashi I, Ito J, Yarita K, Miyaji M. 2002. Pathogenicity and virulence of Candida dubliniensis: comparison with C. albicans. Med. Mycol. 40:249-257.